Skip to main content
Erschienen in: Gastro-News 1/2019

16.02.2019 | Hepatitis B | fortbildung

Hepatologie — Teil 1: Hepatitis-B-Biomarker

Neue molekulare Marker zum Management von HBV-Infektionen?

verfasst von: PD Dr. med. Florian van Bömmel, Prof. Dr. med. Thomas Berg

Erschienen in: Gastro-News | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Viele der neuen Hepatitis-B-Biomarker werden zwar schon auf ihren klinischen Einsatz geprüft, ihre biologische Bedeutung ist jedoch ungeklärt und ihre Rolle für ein effektiveres, individuelles Monitoring von Patienten mit chronischen HBV-Infektion noch nicht definiert. Richtig eingesetzt könnten sie aber helfen, das Management von Komplikationen, insbesondere des hepatozelluären Karzinoms, zu optimieren und so das Langzeitüberleben der Patienten zu verbessern.
Literatur
1.
Zurück zum Zitat WHO: GLOBAL HEPATITIS REPORT 2017. Geneva: World Health Organisation 2017 WHO: GLOBAL HEPATITIS REPORT 2017. Geneva: World Health Organisation 2017
3.
Zurück zum Zitat Wedemeyer H, Hofmann WP, Lueth S et al. ALT screening for chronic liver diseases: scrutinizing the evidence. Z Gastroenterol 2010;48:46–55CrossRef Wedemeyer H, Hofmann WP, Lueth S et al. ALT screening for chronic liver diseases: scrutinizing the evidence. Z Gastroenterol 2010;48:46–55CrossRef
4.
Zurück zum Zitat Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73.CrossRef Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73.CrossRef
5.
Zurück zum Zitat Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678–686.CrossRef Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678–686.CrossRef
7.
Zurück zum Zitat Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013;58:546–554.CrossRef Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013;58:546–554.CrossRef
8.
Zurück zum Zitat Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013;57:441–450.CrossRef Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013;57:441–450.CrossRef
9.
Zurück zum Zitat Sun J, Ma H, Xie Q, Xie Y, Sun Y, Wang H, Shi G, Wan M, Niu J, Ning Q, Yu Y, Zhou H, Cheng J, Kang W, Xie Y, Fan R, Wei L, Zhuang H, Jia J, Hou J. Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. J Hepatol. 2016 Oct;65(4):674–682.CrossRef Sun J, Ma H, Xie Q, Xie Y, Sun Y, Wang H, Shi G, Wan M, Niu J, Ning Q, Yu Y, Zhou H, Cheng J, Kang W, Xie Y, Fan R, Wei L, Zhuang H, Jia J, Hou J. Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. J Hepatol. 2016 Oct;65(4):674–682.CrossRef
10.
Zurück zum Zitat Chen J, Zhang DH, Xu CR, Zhu MY, Yang ZT, Gong QM, Yu DM, Zhang XX. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B. J Clin Virol. 2015 Nov;72:88–94.CrossRef Chen J, Zhang DH, Xu CR, Zhu MY, Yang ZT, Gong QM, Yu DM, Zhang XX. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B. J Clin Virol. 2015 Nov;72:88–94.CrossRef
11.
Zurück zum Zitat Gao YH, Meng QH, Zhang ZQ, Zhao P, Shang QH, Yuan Q, Li Y, Deng J, Li T, Liu XE, Zhuang H. On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. World J Hepatol. 2016 Dec 8;8(34):1511–1520CrossRef Gao YH, Meng QH, Zhang ZQ, Zhao P, Shang QH, Yuan Q, Li Y, Deng J, Li T, Liu XE, Zhuang H. On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. World J Hepatol. 2016 Dec 8;8(34):1511–1520CrossRef
12.
Zurück zum Zitat Zhou B, Liu M, Lv G, Zheng H, Wang Y, Sun J, Hou J. Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays. J Viral Hepat. 2013;20:422–429.CrossRef Zhou B, Liu M, Lv G, Zheng H, Wang Y, Sun J, Hou J. Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays. J Viral Hepat. 2013;20:422–429.CrossRef
13.
Zurück zum Zitat Wong DK, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 2007;45:3942–3947.CrossRef Wong DK, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 2007;45:3942–3947.CrossRef
14.
Zurück zum Zitat Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009;81:27–33.CrossRef Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009;81:27–33.CrossRef
15.
Zurück zum Zitat Maasoumy B, Wiegand SB, Jaroszewicz J, Bremer B, Lehmann P, Deterding K, et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015;21:606.e1–e10.CrossRef Maasoumy B, Wiegand SB, Jaroszewicz J, Bremer B, Lehmann P, Deterding K, et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015;21:606.e1–e10.CrossRef
16.
Zurück zum Zitat Song G, Yang R, Rao H, Feng B, Ma H, Jin Q, et al. Serum HBV corerelated antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients. J Med Virol 2016 Aug 9. [Epub ahead of print] Song G, Yang R, Rao H, Feng B, Ma H, Jin Q, et al. Serum HBV corerelated antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients. J Med Virol 2016 Aug 9. [Epub ahead of print]
17.
Zurück zum Zitat Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, et al. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. J Hepatol 2016;65:48–56.CrossRef Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, et al. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. J Hepatol 2016;65:48–56.CrossRef
18.
Zurück zum Zitat Huang H, Wang J, Li W, Chen R, Chen X, Zhang F, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals. J Clin Virol 2018;99-100:71–78.CrossRef Huang H, Wang J, Li W, Chen R, Chen X, Zhang F, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals. J Clin Virol 2018;99-100:71–78.CrossRef
19.
Zurück zum Zitat van Bömmel F, Bartens A, Mysickova A, Hofmann J, Kruger DH, Berg T, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 2015;61:66–76.CrossRef van Bömmel F, Bartens A, Mysickova A, Hofmann J, Kruger DH, Berg T, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 2015;61:66–76.CrossRef
20.
Zurück zum Zitat Gao Y, Li Y, Meng Q, Zhang Z, Zhao P, Shang Q, et al. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment? J Clin Microbiol 2017;55:2972–2982.CrossRef Gao Y, Li Y, Meng Q, Zhang Z, Zhao P, Shang Q, et al. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment? J Clin Microbiol 2017;55:2972–2982.CrossRef
21.
Zurück zum Zitat Huang YW, Takahashi S, Tsuge M, Chen CL, Wang TC, Abe H, et al. Ontreatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. Antivir Ther 2015;20:369–375.CrossRef Huang YW, Takahashi S, Tsuge M, Chen CL, Wang TC, Abe H, et al. Ontreatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. Antivir Ther 2015;20:369–375.CrossRef
22.
Zurück zum Zitat van Bommel F, Wacker J, Brehm M, Krauel A, Dannenberg, R, Grossmann M, Kitrinos KM, Gaggar A, Delaney WE, Bohm S, Berg T. HBV RNA and HBV core-related antigen (HBcrAg) are early serum markers for HBeAg seroconversion in treatment experienced patients receiving tenofovir disoproxil fumarate (TDF)-containing regimens. HEPATOLOGY 2016; 64: 939A–940A van Bommel F, Wacker J, Brehm M, Krauel A, Dannenberg, R, Grossmann M, Kitrinos KM, Gaggar A, Delaney WE, Bohm S, Berg T. HBV RNA and HBV core-related antigen (HBcrAg) are early serum markers for HBeAg seroconversion in treatment experienced patients receiving tenofovir disoproxil fumarate (TDF)-containing regimens. HEPATOLOGY 2016; 64: 939A–940A
23.
Zurück zum Zitat Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol 2013;48:1188–1204.CrossRef Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol 2013;48:1188–1204.CrossRef
24.
Zurück zum Zitat Heermann KH, Goldmann U, Schwartz W, et al. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 1984;52:396–402.PubMedPubMedCentral Heermann KH, Goldmann U, Schwartz W, et al. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 1984;52:396–402.PubMedPubMedCentral
25.
Zurück zum Zitat Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM, Schröder K, Gerlich WH, Glebe D, Berg T, van Bömmel F. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut. 2017 Sep 26. pii: gutjnl-2017-313811. Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM, Schröder K, Gerlich WH, Glebe D, Berg T, van Bömmel F. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut. 2017 Sep 26. pii: gutjnl-2017-313811.
26.
Zurück zum Zitat Liu C, Wu W, Shang H, Lin S, Xun Z, Huang E, Lin J, Yang B, Ou Q. Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients. Clin Chim Acta. 2018 Jun;481:12–19CrossRef Liu C, Wu W, Shang H, Lin S, Xun Z, Huang E, Lin J, Yang B, Ou Q. Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients. Clin Chim Acta. 2018 Jun;481:12–19CrossRef
27.
Zurück zum Zitat Jia W, Song LW, Fang YQ, Wu XF, Liu DY, Xu C, et al. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine 2014;93:e322.CrossRef Jia W, Song LW, Fang YQ, Wu XF, Liu DY, Xu C, et al. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine 2014;93:e322.CrossRef
28.
Zurück zum Zitat Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut 2016;65:313–320.CrossRef Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut 2016;65:313–320.CrossRef
29.
Zurück zum Zitat Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, Hou J, Janssen HLA, Peng J. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clin Gastroenterol Hepatol. 2018 Jun 11. pii: S1542-3565(18)30600-1. Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, Hou J, Janssen HLA, Peng J. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clin Gastroenterol Hepatol. 2018 Jun 11. pii: S1542-3565(18)30600-1.
30.
Zurück zum Zitat Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134–1143.CrossRef Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134–1143.CrossRef
31.
Zurück zum Zitat Lin CL, Liao LY, Wang CS, Chen PJ, Lai MY, Chen DS, et al. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int 2005;25:564–570.CrossRef Lin CL, Liao LY, Wang CS, Chen PJ, Lai MY, Chen DS, et al. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int 2005;25:564–570.CrossRef
32.
Zurück zum Zitat Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006;194:594–599.CrossRef Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006;194:594–599.CrossRef
33.
Zurück zum Zitat Tseng TC, Liu CJ, Yang HC, Chen CL, Yang WT, Tsai CS, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut 2015;64:292–302.CrossRef Tseng TC, Liu CJ, Yang HC, Chen CL, Yang WT, Tsai CS, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut 2015;64:292–302.CrossRef
34.
Zurück zum Zitat Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, Gaggar A, Kitrinos KM, Subramanian GM, Marcellin P, Buti M, Janssen HLA, Gane E, Sozzi V, Colledge D, Hammond R, Edwards R, Locarnini S, Thompson A, Revill PA. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.Gut. 2017 Nov;66(11):2013–2023CrossRef Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, Gaggar A, Kitrinos KM, Subramanian GM, Marcellin P, Buti M, Janssen HLA, Gane E, Sozzi V, Colledge D, Hammond R, Edwards R, Locarnini S, Thompson A, Revill PA. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.Gut. 2017 Nov;66(11):2013–2023CrossRef
35.
Zurück zum Zitat Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41:591–595.CrossRef Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41:591–595.CrossRef
36.
Zurück zum Zitat Jiang DK, Ma XP, Wu X, Peng L, Yin J, Dan Y, Huang HX, et al. Genetic variations in STAT4,C2,HLA-DRB1 and HLA-DQ associated with risk of hepatitis B virus-related liver cirrhosis. Sci Rep 2015;5:16278.CrossRef Jiang DK, Ma XP, Wu X, Peng L, Yin J, Dan Y, Huang HX, et al. Genetic variations in STAT4,C2,HLA-DRB1 and HLA-DQ associated with risk of hepatitis B virus-related liver cirrhosis. Sci Rep 2015;5:16278.CrossRef
37.
Zurück zum Zitat Hu HH, Liu J, Lin YL, Luo WS, Chu YJ, Chang CL, et al; The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B. Gut 2016;65:1514–1521.CrossRef Hu HH, Liu J, Lin YL, Luo WS, Chu YJ, Chang CL, et al; The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B. Gut 2016;65:1514–1521.CrossRef
38.
Zurück zum Zitat Cao P, Yang A, Wang R, Xia X, Zhai Y, Li Y, Yang F, Cui Y, Xie W, Liu Y, Liu T, Jia W, Jiang Z, Li Z, Han Y, Gao C, Song Q, Xie B, Zhang L, Zhang H, Zhang J, Shen X, Yuan Y, Yu F, Wang Y, Xu J, Ma Y, Mo Z, Yu W, He F, Zhou G. Germline Duplication of SNORA18L5 Increases Risk for HBV-related Hepatocellular Carcinoma by Altering Localization of Ribosomal Proteins and Decreasing Levels of p53. Gastroenterology. 2018 Apr 24. pii: S0016-5085(18)30481-5. Cao P, Yang A, Wang R, Xia X, Zhai Y, Li Y, Yang F, Cui Y, Xie W, Liu Y, Liu T, Jia W, Jiang Z, Li Z, Han Y, Gao C, Song Q, Xie B, Zhang L, Zhang H, Zhang J, Shen X, Yuan Y, Yu F, Wang Y, Xu J, Ma Y, Mo Z, Yu W, He F, Zhou G. Germline Duplication of SNORA18L5 Increases Risk for HBV-related Hepatocellular Carcinoma by Altering Localization of Ribosomal Proteins and Decreasing Levels of p53. Gastroenterology. 2018 Apr 24. pii: S0016-5085(18)30481-5.
39.
Zurück zum Zitat Zeybel M, Vatansever S, Hardy T, Sarı AA, Cakalağaoğlu F, Avcı A, et al. DNA methylation profiling identifies novel markers of progression in hepatitis B-related chronic liver disease. Clin Epigenetics 2016;8:48.CrossRef Zeybel M, Vatansever S, Hardy T, Sarı AA, Cakalağaoğlu F, Avcı A, et al. DNA methylation profiling identifies novel markers of progression in hepatitis B-related chronic liver disease. Clin Epigenetics 2016;8:48.CrossRef
Metadaten
Titel
Hepatologie — Teil 1: Hepatitis-B-Biomarker
Neue molekulare Marker zum Management von HBV-Infektionen?
verfasst von
PD Dr. med. Florian van Bömmel
Prof. Dr. med. Thomas Berg
Publikationsdatum
16.02.2019
Verlag
Springer Medizin
Erschienen in
Gastro-News / Ausgabe 1/2019
Print ISSN: 1869-1005
Elektronische ISSN: 2520-8667
DOI
https://doi.org/10.1007/s15036-019-0537-0

Weitere Artikel der Ausgabe 1/2019

Gastro-News 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.